Arrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) to a sell rating in a research note released on Tuesday.

ARWR has been the topic of several other reports. B. Riley restated a “buy” rating and set a $55.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. Piper Sandler reaffirmed an “overweight” rating and set a $62.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, October 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.33.

Arrowhead Pharmaceuticals Trading Down 13.3 %

ARWR stock opened at $18.57 on Tuesday. Arrowhead Pharmaceuticals has a 12-month low of $17.05 and a 12-month high of $39.83. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -3.98 and a beta of 0.93. The business’s 50-day moving average is $20.11 and its 200 day moving average is $23.42.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp raised its stake in shares of Arrowhead Pharmaceuticals by 42.5% in the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 354 shares in the last quarter. Headlands Technologies LLC raised its stake in shares of Arrowhead Pharmaceuticals by 7,696.8% in the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 2,386 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $52,000. Meeder Asset Management Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 3,333 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at about $96,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.